Literature DB >> 1592542

Comparison of absorption rates in bioequivalence studies of immediate release drug formulations.

R Schall1, H G Luus.   

Abstract

For immediate release drug formulations, the maximum concentration (Cmax), the time to the maximum concentration (tmax), the mean residence time (MRT), and recently, the Cmax/AUC ratio have been suggested as absorption rate characteristics. Several authors have used simulation studies to investigate the relative merits of these characteristics. In contrast, we investigate here the "true" relationships between these four characteristics in a more theoretical manner. Specifically, we show that in the one-compartment open model the difference in tmax, and the ratio of the Cmax/AUC ratio of two drug formulations are equivalent characteristics for the comparison of the absorption rate of two drug formulations. In two- or higher compartment models these relationships hold approximately. This provides a powerful argument for the use of the observed Cmax/AUC ratio, rather than tmax, as a measure for the rate of absorption, because it is well-known that Cmax/AUC can be observed with higher precision than tmax. We also show that the difference in MRT for two-drug formulations equals the difference in mean absorption time under very general conditions, and for the one- and the two-compartmental model we prove this explicitly. Thus the difference in MRT emerges as the most direct characteristic of the difference in absorption rates, and in that sense is superior to both the tmax difference and the Cmax/AUC ratio. Based on empirical evidence and the results of simulation studies published in the literature we recommend that for drugs with short elimination half-lives, the difference in MRT is the primary characteristic for the comparison of absorption rates.(ABSTRACT TRUNCATED AT 250 WORDS)

Mesh:

Substances:

Year:  1992        PMID: 1592542

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  13 in total

1.  Novel direct curve comparison metrics for bioequivalence.

Authors:  J E Polli; A M McLean
Journal:  Pharm Res       Date:  2001-06       Impact factor: 4.200

Review 2.  Measures of exposure versus measures of rate and extent of absorption.

Authors:  M L Chen; L Lesko; R L Williams
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Bioequivalence assessment of generic drugs: an American point of view.

Authors:  R Patnaik; L J Lesko; K Chan; R L Williams
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

4.  Absorption rate vs. exposure: which is more useful for bioequivalence testing?

Authors:  T N Tozer; F Y Bois; W W Hauck; M L Chen; R L Williams
Journal:  Pharm Res       Date:  1996-03       Impact factor: 4.200

Review 5.  Bioequivalence of controlled-release calcium antagonists.

Authors:  R Schall; F R Müller; F O Müller; H G Luus
Journal:  Clin Pharmacokinet       Date:  1997-01       Impact factor: 6.447

Review 6.  Requirements for generic antiepileptic medicines: a clinical perspective.

Authors:  Eugen Trinka; Günter Krämer; Martin Graf
Journal:  J Neurol       Date:  2011-06-11       Impact factor: 4.849

7.  Bioavailability of immediate- and extended-release formulations of glipizide in healthy male volunteers.

Authors:  Sanju Dhawan; Bhupinder Singh; Santosh Kumar Garg; Debasish Hota; Radharaman Jiban Dash; Anil Kumar Singla; Vivek Ranjan Sinha
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Lack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.

Authors:  L Duursema; F O Müller; R Schall; M V Middle; H K Hundt; G Groenewoud; V W Steinijans; H Bliesath
Journal:  Br J Clin Pharmacol       Date:  1995-06       Impact factor: 4.335

9.  Cubic spline functions and polynomials for calculation of absorption rate.

Authors:  J Popović
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Oct-Dec       Impact factor: 2.569

10.  Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.

Authors:  Jorge F Pérez-Oliva; Martha Casanova-González; Idrian García-García; Pedro J Porrero-Martín; Carmen M Valenzuela-Silva; Tairí Hernández-Montero; Marcia Lagarde-Ampudia; Yuri Casanova-Kutsareva; Yisel Avila-Albuerne; Alicia Vargas-Batista; Hailen Bobillo-López; Raúl Herrera-Valdés; Pedro A López-Saura
Journal:  BMC Nephrol       Date:  2005-05-23       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.